Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial Cystitis.

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 12

Inclusion Criteria

- Males and females aged 18 years, or older
- Subject has BPS/IC for a period of at least 9 months prior to screening, as determined by patient history:
- patient had cystoscopy with hydrodistension and cold biopsy
- patient has used oral medication: anticholinergic, NSAID and
tricyclic antidepressant
- patient has used intravesical instillations with cystistat, or ura-cyst, or
bladder cocktails, or heparin, or oxybutinin
- Subject has Visual Analog Scale (VAS) more than 5
- Subject has daytime voiding frequency more than 7
- Subject has night-time voiding frequency more than 2
- Those subjects taking anticholinergic medication, NSAID or tricyclic antidepressant use a stable dose and they are willing to maintain the dose during the study
- Patients must be willing to use clean intermittent catheterization to empty the bladder

Exclusion Criteria

- Patient is pregnant, or patients who want to become pregnant during the study
- Patient has an active urinary tract infection or recurrent urinary tract infections
(> 5 urinary tract infections a year)
- Patient has a chronic or bacterial prostatitis
- Patient has a vaginitis
- Patient has an active sexually transmitted diseases
- Patient has urolithiasis
- Patient has an urethra or bladder diverticulum
- Patient has carcinoma of the uterus, cervix, vagina, urethra or prostate
- Patient has carcinoma in situ / malignancy of the bladder
- Patient has chemical-, tuberculous- or radiation cystitis
- Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diatheses.
- Patient has any medical condition that may put the patient at increased risk with exposure to BTX-A including diagnosed myasthenia gravis, Eaton Lambert syndrome or amyotrophic lateral sclerosis
- Patient discontinued anticholinergic, NSAID or antidepressant medication for bladder pain < 14 days prior to screening
- Patient using intravesical instillations, or used it 4 weeks prior to screening
- Patient using neuromodulations devices for treatment of BPS/IC
- Patient is breastfeeding
- Patient has a post void residual volume above 200 ml
- Patients who will use neuromuscular blocking agents in the period of three days before until eight weeks after study treatment
- Patients who will use aminoglycoside antibiotics the period of three days before until eight weeks after study treatment

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main parameter is the Visual Analog Scale (VAS) score as recorded by<br /><br>patient McGill Pain Questionnaire Dutch Language Version (MPQ-DLV). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary parameters are the number of episodes of voiding as recorded by<br /><br>patient bladder dairy and the quality of life as determined using the<br /><br>questionnaire Short Form-36 (SF-36).</p><br>

Related Trials